Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia - IMIDAS(Inter-Michinoku dasatinib study) 1st Line

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006358

Enrollment

Registered

2011-09-16

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Myeloid Leukemia

Interventions

Dasatinib will be administered at 100mg once daily for 12 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia

Exclusion criteria

Exclusion criteria: Previous treatment with TKI or INF

Design outcomes

Primary

Measure	Time frame
A Major molecular response(MMR)rate at 12 months after the intiation of Dasatinib treatment	—

Countries

Japan

Contacts

Public ContactKAZUNORI MURAI

Iwate Medical Unversity,Internal Medicine hematology/oncology

kmurai@iwate-med.ac.jp0196515111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026